Apnimed Q2 FY26 net income swings to USD 125.94 million; revenue falls 29.38% to USD 12.08 million - APMD News | RalliesApnimed Q2 FY26 net income swings to USD 125.94 million; revenue falls 29.38% to USD 12.08 million
A
APMD• Q2 results
- Apnimed swung to net income of $125.94 million in Q2 2026 from a net loss a year earlier.
- Revenue fell 29.38% to $12.08 million, while R&D expenses dropped 38% to $9.9 million.
- General and administrative costs more than doubled to $12.67 million on higher legal services and launch-readiness spending.
Regulatory update and cash position
- FDA accepted the NDA for AD109, proposed proprietary name Oxnimbi, setting a PDUFA target action date of Feb. 28, 2027.
- Cash and cash equivalents totaled $172.8 million at June 30; the company later completed a $220.8 million IPO at $16 a share.
OSBC
•
